Study to evaluate safety and efficacy in adult subjects with ITP
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-98 ...
Product Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: anti-CD40LProduct Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: a ...
Bristol-Myers Squibb International Corporation
NULL
Not Recruiting
Female: yes Male: yes
80
Phase 2
United States;Canada;Poland;Australia;Russian Federation;Georgia;Moldova, Republic of
Study to evaluate safety and efficacy in adult subjects with ITP
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-9 ...
Product Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: anti-CD40LProduct Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: a ...
Bristol-Myers Squibb International Corporation
NULL
Not Recruiting
Female: yes Male: yes
80
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...